IQVIA slides after Q4 results as earnings outlook underwhelms
Source: SeekingAlpha
2026-02-05 10:49:39 ET
More on IQVIA
- IQVIA: Increasingly Indispensable In Drug Development
- IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript
- IQVIA Q4 2025 Earnings Preview
- CROs fall as FDA head Makary says drug approvals will require fewer trials
- Seeking Alpha’s Quant Rating on IQVIA
Read the full article on Seeking Alpha
For further details see:
IQVIA slides after Q4 results as earnings outlook underwhelms
Fortrea Holdings Inc.
NASDAQ: FTRE
FTRE Trading
2.37% G/L:
$9.08 Last:
590,660 Volume:
$8.77 Open:
FTRE Latest News
February 26, 2026 06:00:00 am
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
FTRE Stock Data
$1,263,108,000
91,476,000
0.29%
136
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
